To determine whether TRAIL and VEN alone or in combination are effective against AML cells expressing TP53INP2 in vivo, a PDX mouse model was generated by injecting mice with leukemic cells from AML patient #3 carrying NPM1-mA. The gene discussed is NPM1; the disease is acute myeloid leukemia.